Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituxan and BEAM with Autologous Transplant for Lymphoma
NCT00007852Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Sep 2000
- Primary completion
- Jan 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in B-cell non-Hodgkin lymphoma, sponsored by University of Nebraska. Primary endpoint: Complete and Partial Response Rate at 100 days. Started Sep 2000; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00007852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00007852.